NPP1 FUSION PROTEINS
The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.
1 . An isolated NPP1 fusion protein, comprising an NPP1 component, and an Fc region of an immunoglobulin, wherein a) the NPP1 component comprises the cysteine-rich region and the C-terminus catalytic domain of NPP1, b) the Fc region is located C-terminally to the NPP1 component, and c) the isolated NPP1 fusion protein has NPP1 enzymatic activity.
2 . The NPP1 fusion protein of claim 1 , wherein said NPP1 enzymatic activity is pyrophosphatase activity, phosphodiesterase activity or pyrophosphatase and phosphodiesterase activity.
3 . The NPP1 fusion protein of claim 1 , wherein said fusion protein is a recombinant protein.
4 . The NPP1 fusion protein of claim 1 , wherein said NPP1 component consists of P99 through D925 of SEQ ID NO: 1.
5 . The NPP1 fusion protein of claim 1 , wherein said fusion protein further comprises a signal peptide.
6 . The NPP1 fusion protein of claim 1 , wherein said fusion protein forms a homodimer.
7 . The NPP1 fusion protein of claim 1 , wherein said fusion protein is a monomer.
8 . The NPP1 fusion protein of claim 1 , wherein said Fc region is fused to the C-terminus of said catalytic domain of NPP1.
9 . An isolated nucleic acid encoding the NPP1 fusion protein of claim 1 .
10 . A replication or expression vector carrying the isolated nucleic acid of claim 9 .